Wednesday, February 1, 2023 | Back issues
Courthouse News Service Courthouse News Service

Pharma Class Action

Arrowhead Pharmaceuticals stock dropped from $9.36 to $1.44 after the failure of its three proposed drugs for liver disease, shareholders claim in a federal class action.

LOS ANGELES – Arrowhead Pharmaceuticals stock dropped from $9.36 to $1.44 after the failure of its three proposed drugs for liver disease, shareholders claim in a federal class action.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...